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commoACKGROUND CONTEXT: Synthetic bone graft substitutes are commonly used in spinal
fusion surgery. Preclinical data in a model of spinal fusion to support their efficacy is an important
component in clinical adoption to understand how these materials provide a biological and mechan-
ical role in spinal fusion.
PURPOSE: To evaluate the in vivo response of a nanosynthetic silicated calcium phosphate putty
(OstP) combined with autograft compared to autograft alone or a collagen-biphasic calcium phos-
phate putty (MasP) combined with autograft in a rabbit spinal fusion model.
STUDY DESIGN: Efficacy of a nanosynthetic silicated calcium phosphate putty as an extender to
autograft was studied in an experimental animal model of posterolateral spinal fusion at 6, 9, 12
and 26 weeks, compared to a predicate device.
METHODS: Skeletally mature female New Zealand White rabbits (70) underwent single
level bilateral posterolateral intertransverse process lumbar fusion, using either autograft
alone (AG), a nanosynthetic silicated calcium phosphate putty (OstP) combined with autograft
(1:1), or a collagen-biphasic calcium phosphate putty (MasP) combined with autograft (1:1).
Iliac crest autograft was harvested for each group, and a total of 2 cc of graft material was
implanted in the posterolateral gutters per side. Fusion success was assessed at all time points
by manual palpation, radiographic assessment, micro-CT and at 12 weeks only using non-
destructive range of motion testing. Tissue response, bone formation and graft resorption
were assessed by decalcified paraffin histology and by histomorphometry of PMMA embed-
ded sections.
RESULTS: Assessment of fusion by manual palpation at the 12 week endpoint showed 7 out of 8
(87.5%) bilateral fusions in the OstP extender group, 4 out of 8 (50%) fusions in the MasP extender
group, and 6 out of 8 (75%) fusions in the autograft alone group. Similar trends were observed with
fusion scores of radiographic and micro-CT data. Histology showed a normal healing response in
all groups, and increased bone formation in the OstP extender group at all timepoints compared to
the MasP extender group. New bone formed directly on the OstP granule surface within the fusion
mass while this was not a feature of the Collagen-Biphasic CaP material. After 26 weeks the OstPatus: Osteo3 ZP Putty (Approved for this indication),
proved for this indication).
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group resulted in bilateral fusions in 3 out of 5 (60%), assessed by manual palpation, and fusion of
only 20 and 0% by radiograph and micro-CT scoring, respectively. Histology at 26 weeks showed
consistent bridging of bone between the transverse processes in the Ost P extender group, but this
was not observed in the MasP extender group.
CONCLUSIONS: The nanosynthetic bone graft substituted studied here, used as an extender to
autograft, showed a progression to fusion between 6 and 12 weeks that was similar to that observed
with autograft alone, and showed excellent fusion outcomes, bone formation and graft resorption at
26 weeks.
CLINICAL SIGNIFICANCE: This preclinical study showed that the novel nanosynthetic sili-
cated CaP putty, when combined with autograft, achieved equivalent fusion outcomes to autograft.
The development of synthetic bone grafts that demonstrate efficacy in such models can eliminate
the need for excessive autograft harvest and results from this preclinical study supports their effec-
tive use in spinal fusion surgery. © 2021 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)Keywords: Posterolateral spinal fusion; Rabbit; Calcium phosphates; Nano-scale morphology; Silicate; SiliconIntroduction
The past two decades has seen a significant number of new
synthetic bone grafts products translated from concept to the
clinic. Many of these, however, are based on traditional con-
cepts, namely macroporous ceramics of the calcium phos-
phate phases hydroxyapatite and/or tricalcium phosphate
(HA+TCP) [1−5], or bioactive glasses based on sodium-cal-
cium-silicate compositions, particularly 45S5 Bioglass [6
−8]. A lack of clinical data on newer products makes compar-
ison with autograft or allograft challenging [9], leading to a
lack of clarity of the efficacy of one bone graft substitute over
another. The definition of a synthetic bone graft substitute is
typically oversimplified, leading to comparisons being made
between different products based on a single common feature.
There are at least 11 chemical and physical variables that
describe fully a synthetic bone graft substitute [10], all of
which can have an influence on bone repair.
A number of calcium phosphate-based synthetic bone
graft substitutes have been developed in the last decade that
build upon the traditional concepts of synthetic bone graft
technology. These include the development of chemically
modified calcium phosphates [11], incorporation of a sub-
micron surface topography to the granules [1,3] and using
nanoscale materials in manufacturing the bone graft [12]. The
efficacy of such materials is typically evaluated by compari-
son to autograft in a pre-clinical model of posterolateral spinal
fusion [5,6,13-15], using the validated Bodenmodel in rabbits
that shows fusion rates with autograft that are similar to this in
humans [16]. A recently published randomised clinical study
compared a microporous synthetic bone graft substitute putty,
comprising a biphasic composition of HA+TCP, in instru-
mented posterolateral fusion, compared to autograft [17].
This level 1 study showed non-inferiority of the synthetic
material to autograft, based on fusion rates after 12 months
from 87 patients.
This study aims to evaluate a novel nanosynthetic sili-
cated calcium phosphate putty in a validated pre-clinicalmodel of posterolateral spinal fusion [5,13,14]. The putty,
when combined with equal amounts of autograft, was com-
pared with a commercially available synthetic bone graft
substitute putty combined with autograft, and both of these
extender groups were compared to the gold standard (auto-
graft alone) after implantation for 6, 9 or 12, which are typi-
cal end-points in such studies. Additionally, the two
synthetic bone graft groups were compared after implanta-
tion for 26 weeks, to provide a longer term evaluation of
bone formation and graft resorption.Materials and methods
Materials
Autograft (AG) bone harvested from the iliac crest was
used as the positive control group. Autograft was combined
with the materials described below (50/50).
Osteo3 ZP Putty (SIRAKOSS Ltd., UK) was used as sup-
plied and is referred to as OstP from this point onwards.
This material contains 1-2 mm diameter granules of a nano-
synthetic silicate-substituted calcium phosphate in a Polox-
amer P407 hydrogel carrier.
Mastergraft Putty (Medtronic, Memphis, TN) was used
as the predicate. Mastergraft Putty (MasP) is composed of
0.5 mm to 1.6 mm diameter granules of biphasic calcium
phosphate (85% B-TCP and 15% hydroxyapatite) dispersed
in a bovine type I collagen [18]. MasP has been used suc-
cessfully as a bone graft extender in rabbit PLF studies
[15].Scanning electron microscopy
Scanning electron microscopy was performed on gran-
ules used to prepare the OstP putty samples; granules were
deposited onto adhesive carbon on aluminium stubs and
coated with a thin layer of Pd/Au. Images were collected
using a Carl Zeiss SIGMA VP Analytical Field Emission
Fig. 1. Preparation of graft volumes for implantation, for OstP (A, B, C)
and MasP (D, E, F). Equivalent volumes of the two test articles and iliac
crest autograft were measured (A, D), manually combined (B, E), then
placed in an open bore syringe to produce 2 cc of graft per syringe (C, F).
J.C. Conway et al. / The Spine Journal 21 (2021) 1925−1937 1927Scanning Electron Microscope (Zeiss, Germany). Images
were collected using accelerating voltages between 15-
20 kV. Average grain sizes were determined by measuring
the longest dimension of >100 grains from multiple images
at 200,000x magnification using Image J (NIH, USA).
Surgical procedure
The in vivo study was approved by the local Animal
Care and Ethics Committee at the (Approval 18/115A) at
the UNSW, Australia. A total of 70 adult female New Zea-
land White rabbits were used in this study, with an alloca-
tion summarized in Table 1. Skeletal maturity of each
rabbit was verified by radiographic confirmation of growth
plate closure at the proximal tibia. The rabbits underwent
single-level bilateral posterolateral intertransverse process
spine arthrodesis at L4−L5 using established protocols
[5,13,14,19].
Surgery followed procedures described elsewhere (add
Crowley paper just accepted [5,19]. Briefly, the iliac crest
was exposed and corticocancellous bone was harvested and
morselised using Rongeur forceps, forming approximately
2cc (~1.6 g) of bone chips ranging from 2 to 5 mm in diam-
eter. For each of OstP and MasP, 1 cc of graft material was
combined with 1 cc of autograft to produce an implantable
volume of 2 cc per side of the spine; MasP was hydrated,
prior to combining with Autograft. For the AG group, 2 cc
of autograft was used per side of the spine. Examples of the
grafts before and after combination with autograft are
shown in Fig. 1(A−D).
Once the rabbit was anesthetised, an incision was made
between L3−L5 and the intermuscular plane between the
multifidous and longissimus muscles was developed at each
level to expose the transverse processes as well as the inter-
transverse membrane. Host bone between the levels was
decorticated using a pneumatic burr. The central region of
the transverse processes were decorticated for a distance of
10mm from the vertebral body and pars. At each side of the
spine 2 cc of bone graft was placed adjacent to the vertebral
body and between the transverse processes, at a distance of
10 mm lateral of the mid-line. Muscle layers were allowed
to return to their natural positions and incisions were then
closed with 3-0 absorbable sutures. Post-surgery pain was
managed with Carprofen (50 mg/ml) at a dose of 4 mg/kg
(0.28 mL) SC immediately post-operative on day 1
(24 hours post procedure) and 2 mg/kg (0.14 mL) SC on
following days (minimum first 3 days post-operatively).
Animals were monitored and observations recorded daily
for the first 7 days then weekly thereafter.Table 1
Study end points for the different test groups, showing the number of animals used
Test Group 0 days 6 weeks
OstP+AG 3 5
MasP+AG 3 5
AG (positive control) - 5Animals were euthanised while under anaesthesia at the
study end points; for each study group this was at 6 (n=5), 9
(n=5), 12 (n=8) and 26 (n=5) weeks after surgery (the auto-
graft only group, AG, did not include a 26-week time point
as the aim of this later time point was to compare the long
term bone formation and graft resorption of the two syn-
thetic bone grafts only). An additional 3 animals were allo-
cated to the two synthetic bone graft test groups to provide
a t0 for histomorphometry, Table 1.
The sample sizes used were based on previous studies
using this same model that have been reported in the litera-
tures. For the 12-week time-point the sample size of n=8 per
group was chosen to achieve a minimum power of 80% and a
level of significance of 5% (two sided) to detect a true differ-
ence in the means of the test and predicate group. The
observed power for lateral bending was 100% while observed
power for flexion extension was 37.9% and 50.4% for flex-
ion-extension and axial rotation, respectively. The sample size
at 6, 9 and 26 weeks was n=5 considering range of motion
was not performed. The sample sizes were chosen to provide
the minimum number of animals to achieve the experimental
endpoints and are consistent with similar published studies.
Faxitron radiography
Radiographs of harvested spines were obtained using a
Faxitron and digital plates (AGFA CR MD4.0 Cassette).
The digital images were processed using an AGFA Digital
Developer and workstation (AGFA CR 75.0 Digitiser
Musica, AGFA, Germany); the DICOM data were con-
verted to JPEG images using ezDICOM medical viewer.
The radiographic status of the posterolateral spinal
arthrodesis for each spine was evaluated from the post-for each end point
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point grading scale [20], as described previously [5,13].
The percentage of successful fusions (grade A) for each
level was determined based on image review by two inde-
pendent observers blinded to both treatment groups and
time points.
Micro-CT
Micro computed tomography scanning (53 microns) was
performed as previously described [5] all animals following
radiography using an Inveon in-vivo micro computed
tomography scanner (Siemens Medical, PA, USA) to obtain
high resolution radiographic images of the spinal fusions in
three planes. Images were examined in the axial, sagittal
and coronal planes to assess the overall quality of the fusion
mass from transverse process to transverse process as per-
formed for the radiographic data. Fusions at the treated lev-
els were reviewed by two trained and experienced
observers in the coronal and sagittal planes in a blinded
manner to treatment and time using the four-point Lenke
radiographic grading score as described above.
Manual palpation
The stability of the treated levels was assessed by man-
ual palpation [16], blinded by two trained and experienced
observers assessed motion in lateral bending and flexion/
extension and compared it to the proximal and distal motion
segments. The segments were graded as either fused (rigid,
no detectable movement at the disc space) or not fused (not
rigid, movement detected at the disc space) [5].
Biomechanical testing
Spines were tested non-destructively with pure moments
using a Denso robot (simVITRO; Cleveland Clinic BioRo-
botics Lab, Cleveland, OH) to avoid off axis moments and
spurious loading as previously reported [5], in axial rotation
(AR), flexion-extension, (FE), and lateral bending (LB).
Moments of 270 Nmm were applied [21] at a rate of 33.3
Nmm per second to a maximum of 300 Nmm and was held
for 15 seconds. A total of 4.5 load − unload cycles were
run in each profile. The last three cycles were analyzed and
a mean value at 270 Nmm was taken for each cycle and
averaged.
Histology and histomorphometry
The spines were fixed for a minimum of 96 hours in 10%
formalin in 0.145 M phosphate buffered saline and cut in
the sagittal plane through the middle of vertebral body. One
side was randomly processed for decalcified paraffin histol-
ogy or undecalcified polymethyl methacrylate (PMMA)
histology. Paraffin histology was used to assess general tis-
sue response and new bone formation. PMMA histology
was used for the quantitative determination of bone forma-
tion and graft resorption based on histomorphometry [5].Specimens were decalcified 10% formic acid in phos-
phate buffered formalin at room temperature for 3 to 4 days
and cut in sagittal plane (~3 mm in thickness), embedded in
paraffin and sectioned (5 microns) using a Leica Microtome
(Leica Microsystems Pty Ltd, North Ryde, Australia). Sec-
tions were stained with H&E and Tetrachrome and exam-
ined in a blinded fashion to qualitatively examine local cell
and tissue responses using an Olympus light microscope
(Olympus, Japan) with a DP72 high-resolution video cam-
era (Olympus, Japan).
PMMA embedded specimens were sectioned in the sag-
ittal plane (~15 micron) using a Leica SP1600 saw-micro-
tome (Leica Microsystems Pty Ltd., North Ryde, Australia)
and stained with methylene blue (Sigma, 1% in 0.1 M borax
buffer, pH 8.5) and basic fuchsin (Sigma, 0.3% in water)
[1]. Three sections were cut from each PMMA block, with
a ~2 mm interval to evaluate the entire fusion mass from
medial to lateral. Low magnification images were used for
histomorphometric analysis [5].
Low magnification images (1.25£, 1 mm scale bar)
from the transverse process, the middle of the fusion
and the other transverse process were used for quantita-
tive analysis. The region-of-interest was determined by
an observer blinded to treatment and time, using a poly-
gon technique [2,5]. The percentage of the graft material
or bone tissue (mineralized bone and bone marrow ele-
ments) was identified by pixel colour and morphology
was determined, and a mean value was obtained, for
each animal based.Statistical analysis
Statistical analysis was performed using GraphPad Prism
(v5, GraphPad Software Inc., USA). Grading of spinal
fusion (manual palpation, radiographic fusion, and micro-
CT fusion) were analysed using a Kruskal-Wallis test with
a Dunn’s post-test for multiple comparisons. Biomechanical
data and histomorphometry data were analysed one-way
ANOVA test followed by a Bonferroni post-test for multi-
ple comparisons. Statistically significant differences were
considered for values of p<.05.Results
Material characterisation
The morphology of the granules in the OstP was irregu-
lar shaped granules with dimensions ranging between 1 mm
and 2 mm, Fig. 2(A), and high magnification images show
that these have a small sub-micron grain size with a rod-
like morphology and have a high level of small sub-micron
pores between the grains, Fig. 2(B). The grain size range
was between 99 and 237 nm, from a total of 116 grains
measured, with a median grain size of 169 nm (standard
deviation [SD]=32). The morphology of the granules in
MasP have been reported in detail elsewhere [18].
Fig. 3. Representative radiographs for (A, D, G) autograft (AG) control,
(B, E, H) OstP+AG, (C, F, I) MasP+AG after the 6, 9 and 12 weeks end-
points, respectively. Radiographs for (J) OstP+AG and (K) MasP+AG after
the 26 week end-point are included. Images selected correspond to the
third sequentially numbered animal for n=5 groups (6, 9 and 26 weeks)
and the fifth for n=8 (12 weeks).
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No post-surgery complications were observed, and no
adverse reactions were observed at any of the end points at
the tissue harvest site, gross necropsy of organs, blood anal-
ysis or vital organ histology (data not shown). All rabbits
were ambulating normally and were clinically normal at
each of the end points. Post-operative radiographs con-
firmed correct placement of the bone grafts.
Radiographic analysis at end-points
Representative radiographs for the three study groups at
the end points of 6, 9, 12 and 26 weeks are shown in Fig. 3.
The radiographs presented correspond to the third sequen-
tially numbered animal at timepoints with n=5, and the fifth
sequentially numbered animal at timepoints with n=8, to
attempt a lack of bias in selecting representative images.
No migration of the bone grafts from the implantation sites
was observed in any of the groups. Radiographs show pro-
gression towards a solid fusion mass in the AG, Fig. 3(A,
D, G), and OstP groups, Fig. 3(B, E, H, J) with increasing
implantation time. For the AG group the individual bone
chips that could be observed at 6 weeks could not be easily
discriminated at 12 weeks, with mineralised bone bridging
the transverse processes. Individual granules were still visi-
ble in the OstP group at 12 weeks, and to a lesser extent at
26 weeks, with evidence of trabecular bone within the
fusion mass. In the MasP group there was a lack of radi-
opaque material in the fusion mass by 12 weeks, Fig. 3(I)
compared to at 6 and 9 weeks, Fig. 3(C, F), where high con-
trast calcium phosphate granules in the graft material can be
observed. With this loss of contrast of the CaP granules, the
morphology of the autologous bone chips can be observed,
with significant gaps within the fusion mass.
Examples of 3D micro-CT reconstructions at the 12
week end point for the autograft control, OstP and MasP
groups are shown in Fig. 4(A−C), respectively; these corre-
spond to the same animals in Fig. 3(G−I). The graft mate-
rial in the autograft control group and the OstP group show
good integration with the transverse processes, with evi-
dence on new bone throughout the fusion mass, Fig. 4(A
and B). Granules can be observed with the graft of the OstP
group, but these are integrated within a trabecular network.
The MasP group shows limited graft material remaining at
the center of the fusion mass, but good integration at the
transverse processes, Fig. 4(C). A full panel of micro-CTFig. 2. SEM images (A, B) of the silicated calcium phosphate granule
component of OstP.reconstructions for all end points are provided in Supple-
mentary Information (Figure S2).
Fusion rate was determined by radiograph grading and
micro-CT grading according to the Lenke scale, with fusion
rate (%) results corresponding to a Lenke Grade A, solid
bilateral fusion, Fig. 5(B and C), respectively. A similar
trend is observed with both gradings, although the grading
of micro-CT data shows lower scoring at 6 weeks. The
autograft (AG) group shows an increase in the fusion rate
with increased implantation time up to 12 weeks, reaching
87.5% fusion rate (7 of 8) with both gradings. The OstP
group showed an increase in fusion rate with time, reaching
62.5% fusion rate (5 of 8) at 12 weeks and 100% (5 of 5) at
26 weeks, respectively, by both gradings. The MasP group
exhibited much lower fusion rates than the other two
groups, by both radiograph grading and micro-CT grading.
Only 12.5% (1 of 8) spines fused at 12 weeks by micro-CT
grading and 0% (0 of 5) after 26 weeks; radiographic grad-
ing provided slightly higher rates of 25% (2 of 8) and 20 %
Fig. 4. Representative 3D micro-CT reconstructions at the 12 week end-
point for (A) autograft (AG) control, (B) OstP+AG, (C) MasP+AG. Images
selected correspond to the fifth sequentially numbered animal (fifth of
eight) for each group.
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points statistically significant differences (p<.05) were only
observed between the autograft control and the MasP group
at 12 weeks, and the OstP and the MasP groups at 26
weeks.Manual palpation
Bilateral fusion of the spines was also assessed by man-
ual palpation, Fig. 5(A), with fusion rate (%) generally
increasing with increased implantation time for each group.
Higher fusion rates (%) were observed for the autograft and
the OstP groups than the MasP groups at 6 and 9 weeks,
and at 12 weeks the manual palpation assessment of bilat-
eral fusion was 75% (6 of 8), 87.5% (7 of 8) and 50% (4 of
8) for the autograft, OstP and MasP groups, respectively. At
26 weeks the fusion rates of the OstP and MasP groups
increased further to 100% (5 out of 5) and 60% (3 of 5),
respectively. No statistically significant differences were
observed between groups at any end point.Fig. 5. Assessment of bilateral spinal fusion by (A) manual palpation, (B)
radiographic grading and (C) micro-CT grading after 6 (n=5), 9 (n=5), 12
(n=8) or 26 (n=5) weeks (no autograft control at 26 weeks). For radiograph
and mCT grading, successful fusion corresponds to a grade A on the Lenke
scale. * p<0.05.Biomechanical assessment
Biomechanical test results of spines at the 12-week end-
point showed that lateral bending range of motion (ROM)
showed significant differences between test groups and
between the non-operated controls, Fig. 6. The autograft
control group and the OstP group showed significantly
lower lateral bending ROM (p<.05) compared to the non-
operated controls, while the mean value for the MasP group
was lower but this was not statistically significant; mean
values§SD are provided in Table 2. Comparing the OstP
and MasP groups showed the lateral bending ROM was sig-
nificantly lower for the OstP group (p<.01). Similar trends
were observed for flexion-extension ROM and axial rota-
tion ROM measurements, with the mean values for the
three test groups being lower than the non-operated control,
but these differences were not statistically significant.Histological evaluation
Low magnification images of whole spine decalcified
histology, with H&E, Fig. 7(A, C, E), or tetrachrome, Fig. 7
(B, D, F) staining for the three study groups at the 12 week
end point provide an overview of the healing response;images are representative sections, with consecutive sec-
tions used for the two stains. Transverse processes are
highlighted in the tetrachrome stained images and autograft
bone and, for OstP and MasP groups, the presence of resid-
ual calcium phosphate bone graft is noted. All sections
show the presence of bone marrow space in the fusion
mass.
Low and high magnification paraffin histology images
with tetrachrome staining of areas close to the transverse
processes, Fig. 8(A−C), or at the center of the fusion mass,
Fig. 8(D−F) for the three groups at 6 weeks are presented.
Higher magnification images of the highlighted regions of
Fig. 6. Biomechanical (ROM) assessment of spinal fusion at 12 weeks. Mean range of motion (˚) by (A) lateral bending, (B) flexion-extension and (C) axial rota-
tion. Data from non-operated controls are included for comparison. Significant differences in lateral bending ROMwere found between OstP+AG and MasP+AG
groups, and between the non-operated controls and both the AG control and OstP+AG groups, * p<0.05 (n=8, except for non-operated controls where n=5)
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Fig. 8(G−I). New bone was observed in the autograft group
near the transverse processes and at the center of the fusion
mass, Fig. 8(A and D), respectively, with the presence of
bone marrow spaces and also chondroblastic tissue which is
evidence of regions of bone forming via endochondral ossifi-
cation (EB). For the OstP group, abundant new bone was
observed bridging between granules, and between granules
and autograft, near the transverse processes, Fig. 8(B) with
bone marrow spaces present. At the center of the fusion mass
the maturity of the bone formed between granules was less
than at the transverse processes or in the autograft group, but
regions of chondroblastic tissue could be observed between
granules, indicative of new bone forming via endochondral
ossification (EB) by the formation of cartilage-like precursor
tissue, Fig. 8(E and H). In the MasP group, new bone could
be observed in some regions near the transverse processes but
in other areas there was fibrous tissue between the granules,
Fig. 8(C). At the center of the fusion mass there was a lack of
new bone adjacent to granules with fibrous tissue present
between granules and within the macropores, Fig. 8(F and I).
No evidence of the Poloxamer gel carrier was observed in
histological sections of the OstP group at 6 weeks.
Low and high magnification paraffin histology images
with tetrachrome staining of regions at the center of the
fusion mass for the OstP, Fig 9(A and C), and MasP, Fig. 9
(B and D), groups at 12 weeks provide a clear comparison
of the progression of the healing response at this stage. In
the OstP group an outer cortical shell can be observed, withTable 2
Results of non-destructive biomechanical testing of spine segments after 12 weeks
Test Group Lateral bending
OstP+AG 4.3§2.2˚ (#, %)
MasP+AG 10.5§3.6˚
AG (positive control) 6.2§4.3˚ (#)
Non-operative control 18.4§5.1˚
Mean range of motion (˚) for lateral bending, flexion-extension and axial rota
Data presented are Mean§SD. (n=8, except the non-operative controls where n=5
cantly different from MasP+AG (p<0.01).abundant trabecular bone and bone marrow formed in the
fusion mass; some granules can still be observed. In the
MasP group, an outer cortical shell is not as clear and less
bone marrow and new bone is visible, and isolated remnant
autograft can be clearly observed. Remnants of the calcium
phosphate granules can be observed and these are sur-
rounded in places with a mixed population of inflammatory
cells and fibrous tissue, Fig. 9(B and D).
This progression in healing extends to the 26-week time
point, with a mature bone repair observed in the fusion
mass of the OstP group, with some granules still observed,
Fig. 10(A and C). In the MasP group, Fig. 10(B and D),
more bone marrow was observed at 26 weeks than at 12
weeks, and more evidence of new bone close to autograft,
and individual granules are not clearly identified. The matu-
rity of bone formed in the fusion mass is much less in the
MasP group than the OstP group.Histomorphometric analysis
Histomorphometry was performed on resin-embedded
sections (examples of these are shown in supplementary
material, Figure S2). An overview of the results is shown in
Fig. 11, comparing the amount of new bone formed, con-
sisting of new bone and bone marrow (%bone), residual
bone graft remaining (%graft), and soft/fibrous tissue pres-
ent (%fibrous), at the 6, 9, 12 and 26 week end points. The
same data with statistical analysis is included in Figure S3,






tion of the spine segments in response to pure moment loading (270 Nm).
). # significantly different from non-operative control (p<0.05); % signifi-
Fig. 7. Low magnification histology images showing the fusion masses of spines 12 weeks after surgery for (A, B) autograft (AG) control group, (c,d) OstP
+AG, and (e,f) MasP+AG. Images are stained with H&E (A, C, E) or tetrachrome (B, D, F). Transverse processes are identified in (B), (D) and (F) by orange
dashed ovals. Calcium phosphate granules of OstP and MagP can be observed at the center of the fusion mass and near the transverse processes (arrows).
Fig. 8. High magnification paraffin histology images (tetrachrome) of (A, D, G) autograft (AG) control, (B, E, H) OstP+AG and (C, F, I) MasP+AG at 6
weeks after surgery. Representative images close to the transverse processes (A−C) or at the center of the fusion mass (d−f) are presented; higher magnifica-
tion images of the regions highlighted by the orange boxes in (D−F) are shown in (G−I). G, CaP granules; AG, autograft; FT, fibrous tissue; EB, endochon-
dral bone formation; NB, new bone; BM, bone marrow.
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Fig. 9. Low and high magnification paraffin histology images (tetra-
chrome) of (A, C) OstP+AG and (B, D) MasP+AG at 12 weeks after sur-
gery. Representative images at the center of the fusion mass (A, B) are
presented; higher magnification images of the regions highlighted by the
orange boxes are shown in (C, D). G, CaP granules; AG, autograft; FT,
fibrous tissue; NB, new bone; BM, bone marrow.
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fibrous tissue with increased implantation time. The OstP
group shows a similar progression with time as the auto-
graft group, and also shows a decrease in the residual graft
with increased time. The progression in these parameters
with time in the MasP group is not so clear. Except for the
9 week time point, there is a trend towards a reduction in
residual graft material with increased time. The amount of
new bone does not show a clear trend and remains at com-
parable levels across the time range. The amount of soft/
fibrous tissue present from 6 to 12 weeks shows a similar
trend to the autograft group, but by 26 weeks the amount of
fibrous tissue increases significantly. There wasFig. 10. Low and high magnification paraffin histology images (tetra-
chrome) of (A, C) OstP+AG and (B, D) MasP+AG at 26 weeks after sur-
gery. Representative images at the center of the fusion mass (A, B) are
presented; higher magnification images of the regions highlighted by the
orange boxes are shown in (C, D). G, CaP granules; AG, autograft; FT,
fibrous tissue; NB, new bone; BM, bone marrow.significantly more total bone in the OstP group than the
MasP group at 9 and 26 weeks, Figure S3(c), and signifi-
cantly more soft/fibrous tissue in the MasP group than the
OstP group at 6 and 26 weeks, Figure S3(d) (p<.05). There
were no statistically significant differences in the amount of
graft material remaining at any of the endpoints between
the OstP and MasP groups, Figure S3(e).
Histomorphometry of samples at 26 weeks, Fig. 12(A
−J), showed that OstP and MasP behaved similarly when
close to the transverse process (TP) (a,c,e,g,i), although the
amount of total new bone formed in the OstP group (73.6§
8.8%) was significantly greater (p<.05) than in the MasP
group (64.0§6.9%), with the opposite trend for soft/fibrous
tissue (14.8§9.45 vs. 30.4§3.6%, respectively, p<.05),
Fig. 12 (E and I). A very different response to the two
groups was observed at the center of the fusion mass (FM)
(b,d,f,h,j), with significantly more total bone in the OstP
group than the MasP group (61.0§24.1% vs. 17.4§16.5%,
p<.01), Fig. 12(F). Comparing the MasP group at the TP
and the center of the FM, the raw data for total bone formed
and soft/fibrous tissue present at the TP, Fig. 12(E and I)
respectively, are very closely distributed around the mean,
whereas there is significant scatter in both at the center of
the FM, Fig. 12(F and J), and there is significantly less bone
and more soft tissue at the center of the FM than at the TP.
There were no significant differences in the amount of graft
material remaining between the two groups at the TP
(15.8§7.2% vs. 17.0§12.4%, p=.43) or the center of the
FM (11.6§3.1% vs. 7.6§5.8%, p=.21), Fig. 12(G and H),
suggesting the resorption profiles of the two bone grafts by
the 26 week time point were similar.Discussion
This primary aim of this study was to compare the pro-
gression towards fusion of two synthetic bone graft substi-
tutes to the gold standard of autograft in a validated
preclinical model of posterolateral fusion between 6 and 12
weeks implantation. The nanosynthetic bone graft substitute
studied here (OstP), used as an extender to autograft, exhib-
ited similar end-points to the autograft control, including
fusion scores, biomechanical data and general histology.
Although autograft bone harvested from the iliac crest
has long been considered the gold standard bone graft, the
complications from this additional procedure, most notably
donor site pain [22,23], have motivated the search for alter-
natives. Considerable research has been carried out in the
development of improved synthetic calcium phosphate-
based bone grafts, which have progressed from the macro-
porous sintered ceramics of hydroxyapatite (HA), b-trical-
cium phosphate (b-TCP) or biphasic calcium phosphate
(BCP) that were the basis of many of the clinically used
bone graft substitutes of the last 20 years. Examples of
these advances include developing synthetic materials that
have microstructures that are closer in size-scale to the min-
eral component of bone [24,25], have a sub-micron
Fig. 11. Overview of histomorphometrical analysis from PMMA-embedded sections showing the data (%) for (A) new bone formed, consisting of new bone
+bone marrow (%bone), (B) residual bone graft material remaining (%graft) and (C) soft/fibrous tissue (%fibrous) in the fusion mass over time, at 6, 9, 12
and 26 weeks (n=8 at 12 weeks, n=5 at all other time points, data represent mean values). Autograft control (AG) not included at 26 weeks. Full data sets
including mean, SEM and statistical analysis available in Figure S2 (supplementary information).
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rosity [11], with these having the effect of increasing the
surface area of the material. For example, decreasing the
grain size of b -TCP granules from 2.50 to 0.81 mm, corre-
sponding with an increase in the surface area from 0.7 to
1.4 m2/g, significantly increased the amount of bone formed
and the amount of material resorbed when implanted both
intramuscularly and in posterolateral fusion in canines after
12 weeks [26]. Similarly, decreasing the median grain size
of BCP granules from 1.52 to 0.6 mm, which was associated
with an increase in surface area from 1.21 to 2.77 m2/g, sig-
nificantly increased the amount of bone formed and the
amount of graft material resorbed when implanted intra-
muscularly in canines up to 12 weeks [3]. The performance
of these BCP granules, including as a putty of the granules
dispersed in a resorbable polymeric carrier, as an extender
to autograft in the rabbit PLF model showed equivalent
fusion rates to an autograft control [5].
In the present study a novel nanosynthetic bone graft
substitute was evaluated as an extender to autograft in a rec-
ognised preclinical model for spinal fusion. The material,
Osteo3 ZP Putty (OstP), consisted of granules of silicated
calcium phosphate in an aqueous poloxamer carrier. The
granules are described as containing approximately 5.8
weight % silicon substituted into the calcium phosphate
phase, and have a porosity >75%; the putty contains 30%
granules and 70% poloxamer gel, by weight. These gran-
ules consist of very small grains (<250 nm) and micropores
(<1 mm), Fig. 2(B). The OstP material was compared with
another putty-like synthetic bone graft substitute, MasP,
which has been characterized extensively elsewhere; briefly
it is a mixture of granules of a biphasic b-TCP and HA at a
ratio of 85:15%, combined with bovine type I collagen
which forms a putty when mixed with water or saline [18].In this study, the synthetic bone grafts were each com-
bined with autograft to produce a volume of 4 cc of a 1:1
mixture per animal, with a graft volume of 2 cc per side of
the spine. The effect of graft volume of autograft in the rab-
bit PLF model has been reported to negatively affect fusion
rates when small volumes (≤1 cc per side) are used, but no
significant difference in fusion rate observed for graft vol-
umes > 1 cc up to 3 cc per side [27]. This is therefore
important when using the rabbit PLF model for studying
synthetic bone grafts as extenders to autograft, as it could
be possible that for a total graft volume of 3 cc per side, the
graft would contain sufficient autograft (1.5 cc) to lead to a
successful fusion, irrespective of the efficacy of the syn-
thetic bone graft. Using a graft volume of 2 cc per side in
the extender groups means that there is insufficient auto-
graft present to lead to typical fusion rates for autograft,
therefore providing a true test of the synthetic graft extender
[28]. Implantations were performed at the L4−L5 vertebral
level which has been shown to have no significant effect on
fusion rate compared to the L5-−L6 level [27,29].
The fusion rate for the positive control group were con-
sistent with reported studies [5,13,19,30]. Biomechanical
analysis of spines at 12 weeks showed a decrease in all
range of motions compared to non-operative controls in the
autograft group, with the decrease in lateral bending ROM
being statistically significant. Progression towards
increased fusion and bone formation throughout the fusion
mass were observed in the autograft group from grading of
the fusions by manual palpation, radiographs, and
micro-CT, and from histology and histomorphometry.
Observations were consistent with previous studies in
our labs and with published studies, confirming that the
autograft group served as an appropriate positive control
arm in this study.
Fig. 12. Detailed histomorphometrical analysis at 26 weeks from PMMA-
embedded sections comparing data from regions near the transverse pro-
cesses (TP) (A, C, E, G, I) and at the center of the fusion mass (FM) (B, D,
F, H, J) for the two synthetic bone grafts materials, OstP and MasP, com-
bined with autograft. The data (%) are for (A and B) new bone formed, (C
and D) bone marrow formed, (E and F) total new bone (new bone+bone
marrow), (G and H) graft material remaining, (I and J) soft tissue. Individ-
ual data points are shown, with horizontal bars showing mean values and
st. dev. (n=5). * p<.05.
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not perform as well as the autograft group, with signifi-
cantly lower fusion rates at 12 weeks by grading of radio-
graphs and micro-CT, Fig. 5, and less total bone formed at6, 9 or 12 weeks, Fig. 11 and S3. Fusion rate by manual pal-
pation for the MasP group, and progression to bone repair
and graft resorption from histology, were observed with
increasing implantation time, but in this study MasP as an
extender to autograft was not equivalent to autograft. A
number of studies have reported the use of MasP, or a com-
parable form Mastergraft Strip, in the rabbit PLF model and
have reported varying responses. When MasP was com-
bined with autograft (50%) and implanted at volumes of 3
cc per side, fusion rates by manual palpation and radio-
graphic scoring after 8 weeks were 73% and 91%, respec-
tively [15], which are significantly greater than any fusion
rate in the present study. When Mastergraft Strip was com-
bined with autograft (50%), again implanting 3 cc of graft
per side, a fusion rate of 75% was determined by manual
palpation and radiographic scoring after 8 weeks [31]. In
contrast, a study of similar design reported a fusion rate by
manual palpation of only 12.5% after 8 weeks for Master-
graft Strip combined with autograft (50%) [32]. In the pres-
ent study a fusion rate of 20% (1/5) at the 9 week time-
point was determined by manual palpation in the MasP
group, but 0% (0/5) by grading of radiographs or micro-CT
reconstructions. Fusion rates by manual palpation increased
to 40 and 60% at 12 and 26 weeks, but these values were
higher than fusion rates by grading of radiographs or micro-
CT reconstructions. This is consistent with the lack of
bridging mineralised tissue/graft in the radiographs and
micro-CT, Fig. 3(I and K) and Fig. 4(C), and lack of new
bridging bone through the fusion mass by histology. The
differences may be a result of different graft volumes used,
or differences in combination of the putty and the autograft.
Separation of the histomorphometry results at the 26 week
end-point into regions close to the transverse processes
(TP) and the center of the fusion mass (FM) showed that
the MasP group performed significantly better close to the
TP than the center of the FM, with more bone formed, less
graft remaining and less soft/fibrous tissue remaining close
to the TP than at the center of the FM, Fig. 12(C, D, E). It is
feasible that a longer time-point may lead to progressive
osteoconduction from the bone formed close to the TPs
throughout the fusion mass and lead to bridging fusions.
The OstP group showed a comparable behaviour to the
autograft control group. No statistically significant differen-
ces were observed in the fusion rates between these two
groups at any endpoint by the three methods of grading,
and no significant differences in any of the measured
ROMs at the 12-week end-point. Excluding the presence of
graft material in the OstP group, the two groups showed a
similar trend in increasing total bone and decreasing soft/
fibrous tissue with increasing implantation time from 6 to
12 weeks. Regions of chondroblastic tissue in the center of
the fusion mass were observed in the histology of the OstP
group and the autograft group at 6 weeks, which is indica-
tive of endochondral bone formation. This may lead to the
progression towards bridging bone through the fusion mass
and to the higher fusion rates observed with these two
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and 12-week end-points supports that OstP is an effective
extender to autograft, providing an alternative to harvesting
large volumes of autograft bone.
The OstP group achieved 100% fusion (5 out of 5) by
manual palpation, radiographic grading and micro-CT grad-
ing at the 26-week endpoint, and for the last two gradings
this fusion rate was statistically greater than the MasP
group. Histomorphometry results of regions close to the TP
and at the center of the FM showed similar results for total
bone formed and graft material remaining for the OstP
group, suggesting that at 26 weeks the progression of bone
formation and fusion were consistent throughout the fusion
mass, as opposed to the bimodal response at the TP and FM
observed in the MasP group at 26 weeks, Fig. 12. Compari-
son of the graft material remaining after 26 weeks showed a
similar amount of material for the two synthetic materials.
MasP is a biphasic calcium phosphate (BCP) composed of
predominantly b-TCP (85%) and these compositions have
been shown to exhibit enhanced resorption in vivo com-
pared to hydroxyapatite (HA)-based ceramic synthetic
materials; the OstP material therefore shows an in vivo
resorption profile that is closer to BCP than HA.
There are some of limitations of this study, most impor-
tantly being that, although this preclinical model exhibits a
comparable level of fusion success for autograft to human,
it may not predict human clinical performance of bone
grafts. The study did not include autograft at the 26-week
endpoint as the aim of this additional time point was to
compare the two synthetic materials; the inclusion of this
would have provided some more context to the observation
of the OstP group achieving 100% fusion (5/5) by all meas-
ures at this time-point. It would be interesting to test differ-
ent graft volumes, but also different amounts of autograft
used as extender (25 and 75%), but this was beyond the
scope of this study. Similarly, the inclusion of earlier (3
weeks), intermediate (18 weeks) and long-term (52 weeks)
end-points could provide a more complete assessment of
progression of healing, fusion, remodelling and graft
resorption. Immunohistochemistry could provide some
extra insights, in particular if there is evidence of graft
influence on the early inflammatory response, in particular
macrophage polarisation, the role of osteoclast activity in
the remodelling of the two graft materials, and possibly the
tissue source of mesenchymal stem cells that led to the for-
mation of chondroblastic tissue at the center of the fusion
mass in the autograft and OstP groups at 6 weeks, Fig. 8(D
and E). The rabbit PLF model has been used extensively to
evaluate various bone graft materials, but it is an uninstru-
mented model and the biomechanics of the rabbit spine are
different to humans. Evaluation of these materials in an
instrumented model of posterolateral spinal fusion would
provide further insight to their performance compared to
autograft, but the data from this study shows that in a
demanding preclinical model the OstP Putty may be used
effectively as a bone graft extender.The OstP material studied here contains silicated cal-
cium phosphate granules with much higher levels of sili-
con/silicate substituted in the apatite structure than other
silicated calcium phosphate bone grafts that have been used
clinically [33,34], but also a much smaller grain size. These
properties have not been correlated with in vivo bone for-
mation in this system, but studies on other systems such as
tricalcium phosphate (b-TCP) and biphasic calcium phos-
phate (BCP) materials have shown that bone formation can
be positively affected by relatively small decreases in grain
size [3,5,26].
In conclusion, the novel nanosynthetic silicate calcium
phosphate (OstP) studied as a bone graft extender in an
established preclinical model of posterolateral fusion exhib-
ited similar performance to autograft alone, with no statisti-
cally significant differences observed between these groups
in fusion grading (manual palpation, radiographs or mCT)
or biomechanical testing at 12 weeks (n=8). The inclusion
of a 26 week time point in this study to compare the two
synthetic bone graft substitutes showed that bone formation
and graft resorption for the OstP material continued beyond
the typical 12 week end point and led to fusion in all ani-
mals by all assessment methods. These findings conclude
that this material demonstrates excellent efficacy as an
extender to autograft in the Boden preclinical model of pos-
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